首页> 外文OA文献 >Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats
【2h】

Simultaneous administration of a low-dose mixture of donor bone marrow cells and splenocytes plus adenovirus containing the CTLA4Ig gene result in stable mixed chimerism and long-term survival of cardiac allograft in rats

机译:同时给予低剂量的供体骨髓细胞和脾细胞混合物以及含有CTLA4Ig基因的腺病毒,可实现稳定的混合嵌合和大鼠心脏异体移植的长期存活

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

T-cell costimulatory blockade combined with donor bone marrow transfusion may induce mixed chimerism, rendering robust tolerance in transplanted organs and cells. However, most protocols entail high doses of donor bone marrow cells (BMCs) or repeated administration of costly agents that block costimulatory pathways, thus delaying clinical development. To circumvent these shortcomings, we developed a strategy in which the dosage of donor BMCs was reduced but compensated by donor splenocytes (SPLCs). Furthermore, repeated administration of costly agents was replaced with a single injection of adenovirus expressing a gene of interest. In rat cardiac transplantation models, cardiac allografts from DA (RT-1a) rats were transplanted heterotopically into the abdomen of LEW (RT-11) recipient rats. Immediately after cardiac transplantation, an adenovirus vector (AdCTLA4Ig; 5 × 109 plaque-forming units) containing the gene for CTLA4Ig was administered to recipients (n = 6) simultaneously with a low dose of donor BMCs (1 × 108/rat) and SPLCs (5 × 107/rat) via the portal vein. The treated LEW recipient rats developed long-lasting mixed chimerism (>10% at >100 days) and exhibited long-term cardiac allografts (mean survival time of > 200 days) compared with control recipients. Moreover, recipients displaying long-lasting mixed chimerism accepted subsequent donor skin allografts while promptly rejecting third-party skin allografts. These results suggest that blockade of the CD28-B7 pathway, using adenovirus-mediated CTLA4Ig gene transfer, in concert with a low dosage of donor BMCs and SPLCs, may represent a feasible strategy to induce stable mixed chimerism and permit long-term survival of cardiac allografts.
机译:T细胞共刺激封锁与供体骨髓输注相结合可能会引起混合嵌合体,从而在移植的器官和细胞中表现出强大的耐受性。但是,大多数方案都需要高剂量的供体骨髓细胞(BMC)或重复施用昂贵的药物来阻断共刺激途径,从而延缓了临床发展。为了避免这些缺点,我们开发了一种策略,其中减少供体BMC的剂量,但用供体脾细胞(SPLC)补偿。此外,用单次注射表达目的基因的腺病毒代替了昂贵药物的重复给药。在大鼠心脏移植模型中,将来自DA(RT-1a)大鼠的心脏同种异体移植异位移植到LEW(RT-11)受体大鼠的腹部。心脏移植后,立即将包含CTLA4Ig基因的腺病毒载体(AdCTLA4Ig; 5×109个噬菌斑形成单位)与低剂量的供体BMC(1×108 /只)和SPLCs一起施予接受者(n = 6) (5×107 /大鼠)通过门静脉。与对照组相比,经治疗的LEW受体大鼠发展出持久的混合嵌合体(> 100天> 10%),并表现出长期的心脏同种异体移植(平均存活时间> 200天)。而且,表现出持久混合嵌合体的接受者接受了随后的供体皮肤同种异体移植,同时迅速拒绝了第三方皮肤同种异体移植。这些结果表明,使用腺病毒介导的CTLA4Ig基因转移与低剂量的供体BMC和SPLC协同阻断CD28-B7途径,可能是诱导稳定的混合嵌合体并允许心脏长期生存的可行策略。同种异体移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号